


Global Congress on Integrated Healthcare

A joint Conference in Collaboration with United Research Forum, UK and Mutah University, Jordan

Under The Patronage of his Excellency Dr Yousef Goussous

May 15 - 16, 2022 | Hotel Crowne Plaza Dead Sea, Jordan



Development of Epirubicin-Loaded Biocompatible Polymer PLA-PEG-PLA Nanoparticles: Synthesis, Characterization, Stability, and In Vitro Anticancerous Assessment

***Salam Massadeh^{1,2*}, Iman Almohammad¹, Eman Barhoush¹, Mostafa Omar^{3,4}, Abdulaziz Almalik^{2,5} and Manal Alaamery^{1,2,*}**

¹Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (MNG-HA), Saudi Arabia.

²KACST-BWH Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Saudi Arabia

³College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia; Ahmedm@ksau-hs.edu.sa

⁴King Abdullah International Medical Research Center, Saudi Arabia

⁵Life sciences and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Saudi Arabia

Abstract

Epirubicin (EPI) is an anti-cancerous chemotherapeutic drug that is an effective epimer of doxorubicin with less cardiotoxicity. Although EPI has fewer side effects than its analog, doxorubicin, this study aims to develop EPI nanoparticles as an improved formula of the conventional treatment of EPI in its free form. Methods: In this study, EPI-loaded polymeric nanoparticles (EPI-NPs) were prepared by the double emulsion method using a biocompatible poly (lactide) poly (ethylene glycol) poly(lactide) (PLA-PEG-PLA) polymer. The physicochemical properties of the EPI-NPs were determined by dynamic light scattering (DLS), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), entrapment efficiency and stability studies. The effect of EPI-NPs on cancer cells was determined by high throughput imaging and flow cytometry. Results: The synthesis process resulted in monodisperse EPI-NPs with a size of 166.93 ± 1.40 nm and an elevated encapsulation efficiency (EE) of 88.3%. In addition, TEM images revealed the spherical uniformness of EPI-NPs with no aggregation, while the cellular studies presented the effect of EPI-NPs on MCF-7 cells' viability; after 96 h of treatment, the MCF-7 cells presented considerable apoptotic activity. The stability study showed that the EPI-NPs remained stable at room temperature at physiological pH for over 30 days. Conclusion: EPI-NPs were successfully encapsulated within a highly stable biocompatible polymer with minimal loss of the drug. The used polymer has low cytotoxicity and EPI-NPs induced apoptosis in estrogen-positive cell line, making them a promising, safe treatment for cancer with less adverse side effects.

References

1. Massadeh, S.; Omer, M.E.; Alterawi, A.; Ali, R.; Alanazi, F.H.; Almutairi, F.; Almotairi, W.; Alobaidi, F.F.; Alhelal, K.; Almutairi, M.S.; et al. Optimized Polyethylene Glycolylated Polymer-Lipid Hybrid

Global Congress on Integrated Healthcare

A joint Conference in Collaboration with United Research Forum, UK and Mutah University, Jordan

Under The Patronage of his Excellency Dr Yousef Goussous

May 15 - 16, 2022 | Hotel Crowne Plaza Dead Sea, Jordan

Nanoparticles as a Potential Breast Cancer Treatment. *Pharmaceutics* 2020, 12, 666.

- Gewirtz, D. A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin. *Biochem. Pharmacol.* 1999, 57, 727–741.

Biography

Dr. Salam Massadeh is a Research Scientist in the Developmental Medicine Department at the King Abdullah International Medical Research Center (KAIMRC). Dr. Massadeh is leading the therapy development lab under the Developmental Medicine Department (DMD) at KAIMRC. Besides, she is the principle investigator of major research projects, and a co-Investigator of many other research projects related to therapy development, gene therapy, gene discovery and pharmacogenetics. In her current position, she has initiated collaborations with international research groups in her field; she is also keen to work with colleagues from different research areas. Dr. Massadeh has published her research outcomes in international peer reviewed journals. Dr. Massadeh is also a member of editorial boards of scientific journals and scientific books.

Dr. Massadeh is experienced in therapy development, drug delivery systems, bio-nanotechnology, and the use of nanotechnology for gene therapy.

Dr. Salam Massadeh has a PhD degree in the field of Nanotechnology in bio-imaging; from the University of East Anglia, United Kingdom. And a Master's degree, in the field of Drug Delivery Systems, college of pharmacy, University of Reims Champagne Ardennes, France. In addition, she has a Bachelor's degree in Pharmacy from Jordan University of Science and Technology. Dr. Massadeh is Member of the Royal Pharmacists Society (RPS), United kingdom. And a member of the International Federation of Pharmacists (FIP), and several other bodies.